ASH 2021 – Constantine Tam

Constantine Tam gives an overview of the results obtained by the SEQUOIA trial, the advantages and disadvantages of BTKi and BCL2i 1L therapy versus their drawbacks and explains which CLL-patients might benefit from BTK inhibitor monotherapy and who might be better off receiving combination treatment including a BTK inhibitor and how novel BCL2 inhibitors improve CLL treatment compared to the standard agent venetoclax.

Here is the full ASH 2021 report.

More posts